Rhythm Pharmaceuticals Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6
Rhythm Pharmaceuticals heeft een totaal eigen vermogen van $179.5M en een totale schuld van $108.4M, wat de schuld-eigenvermogensverhouding op 60.4% brengt. De totale activa en totale passiva bedragen respectievelijk $381.8M en $202.4M.
Belangrijke informatie
60.4%
Verhouding schuld/eigen vermogen
US$108.37m
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$319.13m |
| Aandelen | US$179.50m |
| Totaal verplichtingen | US$202.35m |
| Totaal activa | US$381.85m |
Recente financiële gezondheidsupdates
Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?
Sep 23
We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely
Nov 03We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate
Jul 23Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans
Apr 01We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully
Oct 24Recent updates
Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?
Sep 23Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck
Sep 22Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)
Aug 29Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)
Jun 12Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 09Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon
May 05Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22
Mar 03Rhythm Pharmaceuticals: Action Too Specific
Feb 23Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price
Jan 08We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely
Nov 03We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate
Jul 23Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing
Jun 17Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 05Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans
Apr 01An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued
Dec 15We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully
Oct 24Rhythm Pharmaceuticals: Revisiting The Investment Thesis
Oct 10Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours
Sep 14Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS
Sep 06Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts
Aug 08Rhythm Pharmaceuticals Q2 2022 Earnings Preview
Aug 01Rhythm Pharma gains as NICE recommends obesity drug
Jul 18Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $357.4M ) RYTM } overtreffen de korte termijn passiva ( $54.7M ).
Langlopende schulden: De kortetermijnactiva RYTM ( $357.4M ) overtreffen de langetermijnschulden ( $147.6M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: RYTM heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van RYTM is de afgelopen 5 jaar gestegen van 0% naar 60.4%.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: RYTM heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.
Voorspelling contante baan: Er zijn onvoldoende gegevens om te bepalen of RYTM voldoende cash runway heeft als de vrije kasstroom blijft groeien of krimpen op basis van historische percentages.